Clinical trials: Pleural Diseases
Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma.
- Conditions
- Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma
- Trial name
- NCT02408016
- Testing
- Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Atrial Fibrillation, Pericardial Effusion
Active Clearance of Chest Tubes After Cardiac Surgery: A Prospective Randomized Controlled Study
The purpose of this study is to assess the effectiveness of the PleuraFlow® Active Tube Clearance (ATC) technology in reducing the rate of postoperative atrial fibrillation (POAF) among post cardiac surgery patients and to…
- Conditions
- Atrial Fibrillation, Pericardial Effusion, Pleural Effusion, Hemothorax
- Trial name
- NCT02808897
- Testing
- Standard drainage, Active Tube Clearance drainage
- Where
- 2 sites in Canada
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Montreal Heart Institute
Pleural Effusion, Malignant, Lung Cancer
Prognostic Factors on Malignant Pleural Effusion
Malignant pleural effusion can occur in up to half of the patients with metastatic disease. It can cause shortness of breath to patients and so far there is no protocol on its management.
- Trial name
- NCT03276715
- Where
- Hong Kong
- Volunteers
- 233 people
- Sponsor
- The University of Hong Kong
Lung Cancer, Non-small Cell, Small Cell Lung Cancer
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.
- Conditions
- Lung Cancer, Non-small Cell, Small Cell Lung Cancer, Pleural Mesothelioma
- Trial name
- NCT05628376
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- University College, London
Pleural Mesothelioma, Asbestos Exposure
Mesothelioma Early Detection by VOCs
This is a two phase study, The first phase (phase 1) will identify potential biomarkers among asbestos exposed individuals with pleural mesothelioma.
- Conditions
- Pleural Mesothelioma, Asbestos Exposure, Pleural Plaque
- Trial name
- MED-VOC (NCT04106973)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Henry Ford Health System
Lung Cancer, Esophageal Cancer
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Background: Certain types of lung, esophageal, or thymic cancers and mesotheliomas have specific antigens (protein molecules) on their surfaces.
- Conditions
- Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma
- Trial name
- NCT01143545
- Testing
- Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Pneumothorax
Efficacy and Analgesic Use During the Therapy of Iatrogenic Pneumothorax Using Pleuralvent™ and Chest Tube
The aim of this clinical trial is to compare the efficiency and analgesic use in the therapy of iatrogenic Pneumothorax when using the Pleuralvent™ system in comparison with large bore chest tubes (catheter 16F).
- Trial name
- ASPIRATE (NCT03700554)
- Testing
- Pleuralvent™, Chest tube
- Where
- Czechia
- Volunteers
- 126 people
- Sponsor
- University Hospital Olomouc
Portal Hypertension, Liver Diseases
Achieving Portal Access With Scorpion Post-Approval Study (APASS)
Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure.
- Conditions
- Portal Hypertension, Liver Diseases, Ascites Hepatic, Hydrothorax
- Trial name
- NCT05765253
- Testing
- Scorpion Portal Vein Access Kit, Cook Transjugular Liver Access Set, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Argon Medical Devices
Empyema, Pleural Effusion
Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion
The purpose of this study is to assess the benefit to patients with empyema or complicated parapneumonic effusion (CPE) using a daily versus twice daily Alteplase regimen of two different dose strategies compared with saline…
- Trial name
- NCT00103766
- Testing
- Alteplase
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- O'Brien, Jeana D., MD, FACP, FCCP
Pleural Effusion
Thoracentesis QI Study
Researchers will compare 3 standard of care methods of pleural fluid drainage during therapeutic thoracentesis. Patients are randomized to manual aspiration, vacuum bottle drainage or wall suction methods.
- Trial name
- NCT05424120
- Testing
- Manual aspiration, Wall suction, Vacuum bottle drainage
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Minnesota
Malignant Pleural Effusion
A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion
Patients with a variety of malignancies can develop malignant pleural effusion (MPE). MPE can cause significant symptoms and result in a marked decrease in quality of life and a poor prognosis.
- Trial name
- NCT05330065
- Testing
- bevacizumab and camrelizumab
- Volunteers
- 55 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Malignant Pleural Mesothelioma, Advanced
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced…
- Trial name
- NCT06031636
- Testing
- Oncolytic Adenovirus H101, Programmed death receptor-1 inhibitor
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Medical University Second Hospital
Non Small Cell Lung Cancer
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people…
- Trial name
- NCT00347412
- Testing
- Paclitaxel, NOV-002, Carboplatin
- Where
- 75 sites in United States, Canada and 10 more
- Volunteers
- 903 people
- Sponsor
- Cellectar Biosciences, Inc.
Malignant Pleural Mesothelioma
Trimodality Therapy for Malignant Pleural Mesothelioma
The role of surgical resection in the management of Malignant Pleural Mesothelioma (MPM) is still controversial. The selection criterion to perform either Extrapleural Pneumonectomy (EPP) or Pleurectomy/Decortication (P/D) is…
- Trial name
- NCT01343264
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- HSK Wiesbaden
Malignant Pleural Mesothelioma
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.
- Trial name
- NCT04162015
- Testing
- Nivolumab, Pemetrexed, Cisplatin or Carboplatin
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pleural Empyema
VATS Surgery Compared to Drainage in the Treatment of Pleural Empyema
Pleura empyema is a frequent disease with a high morbidity and a mortality rate of approximately 15%. Pleura empyema is characterized by the passage of three stages (I - III).
- Trial name
- FIVERVATS (NCT04095676)
- Testing
- VATS group, Drain and intrapleural therapy group
- Where
- 3 sites in Denmark
- Volunteers
- 184 people
- Sponsor
- Thomas Decker Christensen
Advanced Solid Tumor, Advanced Cancer
AMT-151 in Patients With Selected Advanced Solid Tumours
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer
- Trial name
- NCT05498597
- Testing
- AMT-151
- Where
- 9 sites in Australia, China
- Volunteers
- 30 people
- Sponsor
- Multitude Therapeutics Inc.
Tuberculosis, Pleural
Diagnostic Utility of Mycobacterium Tuberculosis Cell-free DNA
Tuberculosis (TB) is one of the major global health threats and is the second leading infectious cause of death after COVID-19 in 2022.
- Trial name
- MYDNITE-2 (NCT06439810)
- Testing
- Mycobacterium tuberculosis (MTB) cell-free DNA (cfDNA)
- Where
- Hong Kong
- Volunteers
- 400 people
- Sponsor
- Chinese University of Hong Kong
Fallopian Tube Cancer, Metastatic Cancer
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00993655
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 50 sites in United States, Canada and 2 more
- Volunteers
- 275 people
- Sponsor
- Canadian Cancer Trials Group
End Stage Liver Diseases
Analysis of Respiratory System Mechanics and Inflammatory Response During Orthotopic Liver Transplantation (SPPLIT Trial)
During orthotopic liver transplantation (OLT), respiratory system function may be severely impaired for several reasons including anaesthesia effects, hyperdynamic volume state with fluid overload and ischemia reperfusion injury.
- Trial name
- SPPLIT (NCT02119585)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Turin, Italy